Silexion Therapeutics Corp
For the period ended Sep 30, 2024. Filed Nov 14, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 14, 2024
SLXN$0.11-12.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations (unaudited)
| Nine months ended September 30 | Three months ended September 30, | |||
|---|---|---|---|---|
| 2024 | 2023 | 2024 | 2023 | |
| U.S. dollars in thousands · U.S. dollars in thousands · U.S. dollars in thousands | ||||
| OPERATING EXPENSES: | ||||
| Research and development (including $1,796 and $51 from related party for the nine months period ended September 30, 2024 and 2023, respectively, and including $1,762 and $17 from related party for the three months period ended September 30, 2024 and 2023, respectively) | $4,944 | $2,451 | $3,217 | $535 |
| General and administrative (including $2,972 and $36 from related party for the nine months period ended September 30, 2024 and 2023, respectively, and including $2,948 and $12 from related party for the three months period ended September 30, 2024 and 2023, respectively) | 5,727 | 502 | 4,819 | 196 |
| TOTAL OPERATING EXPENSES | 10,671 | 2,953 | 8,036 | 731 |
| OPERATING LOSS | 10,671 | 2,953 | 8,036 | 731 |
| Financial expenses (income), (including $(47) and $40 from related party for the nine months period ended September 30, 2024 and 2023, respectively, and including $(182) and $40 from related party for the three months period ended September 30, 2024 and 2023, respectively) | 4,092 | 449 | 3,822 | 72 |
| LOSS BEFORE INCOME TAX | $14,763 | $3,402 | $11,858 | $803 |
| INCOME TAX | 9 | 26 | 2 | 6 |
| NET LOSS | $14,772 | $3,428 | $11,860 | $809 |
| Attributable to: | ||||
| Equity holders of the Company | $14,696 | $3,214 | $11,851 | $787 |
| Non-controlling interests | 76 | 214 | 9 | 22 |
| $14,772 | $3,428 | $11,860 | $809 | |
| LOSS PER SHARE, BASIC AND DILUTED | $5.60 | $3.20 | $2.03 | $0.78 |
| WEIGHTED AVERAGE NUMBER OF ORDINARY SHARES OUTSTANDING USED IN COMPUTATION OF BASIC AND DILUTED LOSS PER SHARE | 2,622,655 | 1,005,531 | 5,828, 109 | 1,005,531 |
F - 6
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OFCHANGES IN REDEEMABLE CONVERTIBLE PREFERRED SHARES AND CAPITAL DEFICIENCY
(U.S. dollars in thousands, except per share data)
| Redeemable Convertible Preferred Shares · Ordinary shares · Additionalpaid-in Capital · Accumulated deficit · Total capital deficiency · Total redeemable convertible preferred shares and contingently redeemable non-controlling interests, net of capital deficiency | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Series A preferred shares · Series A-1 preferred shares · Series A-2 preferred shares · Series A-3 preferred shares · Series A-4 preferred shares · Contingently redeemable non-controlling interests | ||||||||||||||||||
| Shares · Amount · Shares · Amount · Shares · Amount · Shares · Amount · Shares · Amount · Amount · Shares · Amount | ||||||||||||||||||
| BALANCE AT JANUARY 1, 2023 | 388,088 | $7,307 | 91,216 | $2,392 | 45,458 | $2,264 | 63,331 | $2,683 | - | - | $3,586 | 873,665 | * | $11,204 | $(21,869) | $(10,665) | $7,567 | |
| CHANGES DURING THE NINE MONTHS PERIOD ENDED SEPTEMBER 30, 2023 (unaudited): | ||||||||||||||||||
| Issuance of Preferred A-4 shares, net of issuance cost | 21,717 | $411 | 1 | 1 | 412 | |||||||||||||
| Share-based compensation | 96 | 96 | 96 | |||||||||||||||
| Net loss | (214) | (3,214) | (3,214) | (3,428) | ||||||||||||||
| BALANCE AS OF SEPTEMBER 30, 2023 | 388,088 | $7,307 | 91,216 | $2,392 | 45,458 | $2,264 | 63,331 | $2,683 | 21,717 | $411 | $3,372 | 873,665 | * | $11,301 | $(25,083) | $(13,782) | $4,647 | |
| BALANCE AT JANUARY 1, 2024 | 388,088 | $7,307 | 91,216 | $2,392 | 45,458 | $2,264 | 63,331 | $2,683 | 21,717 | $411 | $3,420 | 873,665 | * | $11,335 | $(26,811) | $(15,476) | $3,001 | |
| CHANGES DURING THE NINE MONTHS PERIOD ENDED SEPTEMBER 30, 2024 (unaudited): | ||||||||||||||||||
| Exercise of options | 124,020 | ** | * | * | * | |||||||||||||
| Share-based compensation | 707,905 | * | 5,862 | 5,862 | 5,862 | |||||||||||||
| Issuance of convertible preferred shares upon net exercise of warrants | 1,257 | 8,320 | 334 | - | - | - | - | 334 | ||||||||||
| Net loss | (76) | 76 | (14,772) | (14,696) | (14,772) | |||||||||||||
| Conversion of convertible preferred shares and noncontrolling interests upon the effectiveness of the SPAC Merger (see Note 1(d)) | (388,088) | $(7,307) | (92,473) | $(2,392) | (45,458) | $(2,264) | (63,331) | $(2,683) | (30,037) | $(745) | $(3,344) | 4,302,651 | 1 | 18,734 | 18,735 | - | ||
| Issuance of ordinary shares upon Transactions (see Note 1(d)) | 3,756,372 | * | * | * | ||||||||||||||
| Issuance of ordinary shares for ELOC holders | 1,415,418 | * | 996 | 996 | 996 | |||||||||||||
| BALANCE AS OF SEPTEMBER 30, 2024 | - | - | - | - | - | - | - | - | - | - | - | 11,180,031 | $1 | $37,003 | $(41,583) | $(4,579) | $(4,579) | |
** Represents fully vested pre-funded options for the Company’s ordinary shares at an exercise price of $0.003 or 0.0007 NIS per share
F - 7
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN REDEEMABLE CONVERTIBLE PREFERRED SHARES AND CAPITAL DEFICIENCY
(U.S. dollars in thousands, except per share data)
| Redeemable Convertible Preferred Shares · Ordinary shares · Additionalpaid-in Capital · Accumulated deficit · Total capital deficiency · Total redeemable convertible preferred shares and contingently redeemable non-controlling interests, net of capital deficiency | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Series A preferred shares · Series A-1 preferred shares · Series A-2 preferred shares · Series A-3 preferred shares · Series A-4 preferred shares · Contingently redeemable non-controlling interests | |||||||||||||||||
| Shares · Amount · Shares · Amount · Shares · Amount · Shares · Amount · Shares · Amount · Amount · Shares · Amount | |||||||||||||||||
| BALANCE AT JUNE 30, 2023 | 388,088 | $7,307 | 91,216 | $2,392 | 45,458 | $2,264 | 63,331 | $2,683 | 21,717 | $411 | $3,394 | 873,665 | * | $11,269 | $(24,296) | $(13,027) | $5,424 |
| CHANGES DURING THE THREE MONTHS PERIOD ENDED SEPTEMBER 30, 2023 (unaudited): | |||||||||||||||||
| Issuance of Preferred A-4 shares, net of issuance cost | |||||||||||||||||
| Share-based compensation | 32 | 32 | 32 | ||||||||||||||
| Net loss | (22) | (787) | (787) | (809) | |||||||||||||
| BALANCE AS OF SEPTEMBER 30, 2023 | 388,088 | $7,307 | 91,216 | $2,392 | 45,458 | $2,264 | 63,331 | $2,683 | 21,717 | $411 | $3,372 | 873,665 | * | $11,301 | $(25,083) | $(13,782) | $(4,647) |
| BALANCE AT JUNE 30, 2024 | 388,088 | $7,307 | 91,216 | $2,392 | 45,458 | $2,264 | 63,331 | $2,683 | 21,717 | $411 | $3,353 | 997,685 | * | $11,399 | $(29,656) | $(18,257) | $153 |
| CHANGES DURING THE THREE MONTHS PERIOD ENDED SEPTEMBER 30, 2024 (unaudited): | |||||||||||||||||
| Share-based compensation | 707,905 | * | 5,798 | 5,798 | 5,798 | ||||||||||||
| Issuance of convertible preferred shares upon net exercise of warrants | 1,257 | 8,320 | 334 | - | - | 334 | |||||||||||
| Net loss | (9) | 76 | (11,927) | (11,851) | (11,860) | ||||||||||||
| Conversion of convertible preferred shares and noncontrolling interests upon the effectiveness of the SPAC Merger (see Note 1(d)) | (388,088) | $(7,307) | (92,473) | $(2,392) | (45,458) | $(2,264) | (63,331) | $(2,683) | (30,037) | $(745) | $(3,344) | 4,302,651 | 1 | 18,734 | 18,735 | - | |
| Issuance of ordinary shares upon Transactions (see Note 1(d)) | 3,756,372 | * | * | * | * | ||||||||||||
| Issuance of ordinary shares for ELOC holders, net of issuance cost, see Note 3(d) | 1,415,418 | * | 996 | 996 | 996 | ||||||||||||
| BALANCE AS OF SEPTEMBER 30, 2024 | - | - | - | - | - | - | - | - | - | - | - | 11,180,031 | $1 | $37,003 | $(41,583) | $(4,579) | $(4,579) |
F - 8
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.